PDCD1 and neoplasm: In a gene-encoded format, systemic AAV8 delivery of an anti-PD-1 nanobody (Nb11) under a CAG promoter maintained serum levels in the μg/mL range and prevented tumor formation in ~30% of mice after MC38 challenge, with significant survival benefit and low toxicity (172).